© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 18, 2022
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology.
A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.
November 09, 2021
Shaji Kumar, MD, discusses how risk assessments and new drug combinations could influence treatment of patients with newly diagnosed multiple myeloma.
October 29, 2020
Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.
April 17, 2020
Shaji K. Kumar, MD, discusses how patients with multiple myeloma respond to different types of therapy.
October 26, 2017
Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses the management of newly diagnosed patients with multiple myeloma.
December 10, 2013
Shaji K. Kumar, MD, discusses the results of a phase II trial of single agent MLN9708 in patients with relapsed multiple myeloma not refractory to bortezomib.